LENZ Therapeutics (LENZ) Total Non-Current Liabilities (2020 - 2024)

LENZ Therapeutics (LENZ) has 5 years of Total Non-Current Liabilities data on file, last reported at $11.2 million in Q4 2024.

• Total Non-Current Liabilities for Q4 2024 came in at $11.2 million, down 40.4% year-over-year; the trailing twelve-month figure through Dec 2024 was $11.2 million (down 40.4% YoY), and the FY2024 annual result was $11.2 million, down 40.4% from the prior year.
• Total Non-Current Liabilities advanced to $11.2 million in Q4 2024 per LENZ's latest filing, from $8.7 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $62.9 million in Q2 2023 and troughed at $7.9 million in Q2 2021.
• A 5-year average of $23.6 million and a median of $17.0 million in 2021 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities surged 289.41% in 2023, then sank 85.97% in 2024.
• A 5-year view of Total Non-Current Liabilities shows it stood at $32.0 million in 2020, then plunged by 44.03% to $17.9 million in 2021, then retreated by 17.53% to $14.8 million in 2022, then gained by 27.28% to $18.8 million in 2023, then slumped by 40.4% to $11.2 million in 2024.
• Business Quant data shows LENZ's Total Non-Current Liabilities at $11.2 million in Q4 2024, $8.7 million in Q3 2024, and $9.7 million in Q2 2024.